Are we to conclude that BMY and AZN are to hold PAT on their acquisitions to grow their pipelines due to GILD, Roche, Merck, J&J/Janssens, Novartis, and others possibly being a better future business arrangement for them?
Perhaps since there both potential targets is the reasoning.
Market Data 
Markets 
AI
